VYGR
Voyager Therapeutics Inc (VYGR)
Healthcare • NASDAQ • $2.08+9.21%
- Symbol
- VYGR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.08
- Daily Change
- +9.21%
- Market Cap
- $117.07M
- Trailing P/E
- N/A
- Forward P/E
- -1.49
- 52W High
- $5.48
- 52W Low
- $1.89
- Analyst Target
- $14.89
- Dividend Yield
- 0.00%
- Beta
- 1.28
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio…
Company websiteResearch VYGR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.